Precision BioSciences
在场
Precision BioSciences 是一家在股票代码 DTIL (US) 下上市的公司。
高管
查看带有其 20 名主要高管的组织结构图
Precision BioSciences 搜索最多的简介
- Michael Amoroso, Director, President and Chief Executive Officer
- Stanley Frankel, Non-Executive Director
- Sam Wadsworth, Director
高管在Precision BioSciences变化
- Alan List, Chief Medical Officer, 正在办理退休 (新闻发布的2024九月13号).
- Murray Abramson已作为Senior Vice President, Head of Clinical Development加入公司 (新闻发布的2024九月13号).
创建提醒
跟踪 Precision BioSciences 的高管变动
化学
Precision BioSciences 拥有 1,038 家竞争者，其中包括 BASF (德国)、AkzoNobel (荷兰) 和 Air Liquide (法国)。
Popular M&A news in 化学
- Piedmont Lithium and Sayona Mining have announced they will merge (公布2024十一月19号)..
- Rio Tinto has announced the acquisition of Arcadium Lithium (公布2024十月9号).
- Adnoc has announced the acquisition of Covestro (公布2024十月7号).
化学 行业的其他推荐联系人
消息
Precision BioSciences 的最新新闻稿
- Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October | Precision BioSciences
- Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September | Precision BioSciences
- Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update | Precision BioSciences
- Elo Life Systems Announces Strategic Partnership with Dole Food Company with the Goal of Saving the Cavendish Banana | Precision BioSciences
- Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program | Precision BioSciences
- Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update | Precision Biosciences
- Precision BioSciences to Report First Quarter 2020 Financial Results and Present at Bank of America Securities Health Care Conference 2020 | Precision Biosciences
- Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting | Precision Biosciences
- Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources | Precision Biosciences
- Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL | Precision Biosciences
- View more press releases Close
通过电子邮件
